LY3841136 + Tirzepatide for Obesity with Type 2 Diabetes

Phase 2

Recruiting

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

W8M-MC-LAA2: Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliters per minute (mL/min)/1.73 m2

W8M-MC-LAA2: Have a history of acute or chronic pancreatitis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Summary

This trial aims to study the safety and effectiveness of a drug called LY3841136 for managing weight in individuals with Type 2 Diabetes. The study will also look at how combining LY3841136

Who is the study for?

This trial is for adults with obesity or overweight who also have Type 2 Diabetes. Participants will be involved in the study for about 64 weeks to test weight management treatments.

What is being tested?

The study tests LY3841136 and Tirzepatide, alone or combined, for managing weight. Some participants may receive a placebo instead to compare effects.

What are the potential side effects?

Possible side effects of LY3841136 and Tirzepatide could include gastrointestinal issues like nausea or diarrhea, potential low blood sugar levels, fatigue, and injection site reactions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My kidney function is reduced, with an eGFR below 45 mL/min.

Select...

I have a history of pancreatitis.

Select...

I have a history of slow heartbeats.

Select...

I have had symptoms of gallbladder problems in the last 2 years.

Select...

My high blood pressure is not well-controlled.

Select...

I have type 1 diabetes or a history of severe diabetes complications.

Select...

I have liver disease symptoms not caused by nonalcoholic fatty liver disease.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

10Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: LY3841136 Dose 3 + Tirzepatide Dose 3Experimental Treatment2 Interventions